Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen to Develop Trial Dx, Potential Theranostic, for Merck Cancer Program

NEW YORK (GenomeWeb News) — Asuragen Pharmacogenomic Services, a division of Asuragen, will develop a biomarker and pharmacogenomic test for a Merck cancer program, Asuragen said today.
 
Terms of the deal call for Asuragen to apply information from an expression signature identified by Merck's oncology research program to develop a diagnostic assay for use in Merck's cancer clinical trials, and to “potentially form the basis for commercial companion diagnostic tests for oncology therapies.”
 
Under the agreement, Merck will pay Asuragen an undisclosed sum and could pay additional fees depending on the transfer of the diagnostic to clinical reference labs.
 
Asuragen said the test should be completed in 2008.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.